시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 망막질환 치료제 시장 규모, 점유율, 성장 분석 : 질환별, 질환 유형별, 치료 기술별, 투여 경로별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Retinal Disease Therapeutics Market Size, Share, and Growth Analysis, By Disorder (Macular Degeneration, Diabetic Eye Disease), By Disorder Type, By Treatment Techniques, By Route Of Administration, By End-Users, By Region - Industry Forecast 2025-2032
상품코드 : 1780199
리서치사 : SkyQuest
발행일 : 2025년 07월
페이지 정보 : 영문 157 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,300 ￦ 7,590,000
PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,200 ￦ 8,879,000
PDF & Excel (Multiple User License) help
PDF 및 Excel 보고서를 동일 사업장에서 2-5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,100 ￦ 10,168,000
PDF & Excel (Enterprise License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

망막질환 치료제 세계 시장 규모는 2022년에 118억 달러, 2023년 128억 6,000만 달러에서 2031년에는 256억 3,000만 달러로 성장하고, 예측 기간(2024-2031년) CAGR은 9.0%를 보일 전망입니다.

세계 망막질환 치료제 시장은 현재 전 세계적으로 2억 5,300만 명 이상이 앓고 있는 망막질환의 유병률 증가에 힘입어 큰 폭으로 성장하고 있습니다. 이 급증하는 문제는 특히 고령화 사회가 계속 확대되고 50세 이상의 시력 장애가 눈에 띄게 집중되면서 의료 시스템에 점점 더 큰 압력을 가하고 있습니다. 특히 신흥 시장의 당뇨병 유병률 증가에 따른 망막질환 유병률 증가는 이러한 문제를 더욱 악화시키고 있습니다. 그러나 망막질환 치료에 특화된 전문 의료진의 유입과 각국의 상환 제도 강화로 인해 망막 치료의 첨단 치료 및 혁신적 솔루션에 대한 접근성 확대의 길이 열리면서 시장은 수혜를 입을 것으로 예측됩니다.

목차

서론

조사 방법

주요 요약

시장 역학과 전망

주요 시장 인사이트

망막질환 치료제 시장 규모 : 질환별&CAGR(2024-2031)

망막질환 치료제 시장 규모 : 질환 유형별&CAGR(2024-2031)

망막질환 치료제 시장 규모 : 치료 기술별&CAGR(2024-2031)

망막질환 치료제 시장 규모 : 투여 경로별&CAGR(2024-2031)

망막질환 치료제 시장 규모 : 최종사용자별&CAGR(2024-2031)

망막질환 치료제 시장 규모 : 유통 채널별&CAGR(2024-2031)

망막질환 치료제 시장 규모 : 지역별&CAGR(2024-2031)

경쟁 정보

주요 기업 개요

결론과 제안

LSH
영문 목차

영문목차

Global Retinal Disease Therapeutics Market size was valued at USD 11.8 billion in 2022 and is poised to grow from USD 12.86 billion in 2023 to USD 25.63 billion by 2031, growing at a CAGR of 9.0% during the forecast period (2024-2031).

The global retinal disease therapeutics market is experiencing significant growth, driven by the rising prevalence of retinal disorders, which currently affect over 253 million individuals worldwide. This burgeoning issue is putting increasing pressure on healthcare systems, particularly as the aging population continues to expand, with a notable concentration of vision impairment among those over 50 years old. The escalating incidence of retinal diseases, especially in the context of rising diabetes rates in emerging markets, is further compounding the challenge. However, the market is projected to benefit from an influx of specialized healthcare professionals dedicated to retinal disease treatment and enhanced reimbursement frameworks in multiple countries, paving the way for expanding access to advanced therapies and innovative solutions in retinal care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Disease Therapeutics Market Segments Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Disease Therapeutics Market

The increasing incidence of eye-related disorders, particularly in more developed nations, is a significant factor propelling the global market for retinal disease therapeutics. A substantial number of individuals worldwide experience conditions such as diabetic retinopathy and age-related macular degeneration (AMD), underscoring the urgent need for effective treatments. As more individuals become aware of these conditions through enhanced health education initiatives, particularly in developing areas, there is a greater emphasis on seeking early intervention to avoid vision loss. This growing awareness and demand for innovative therapeutic solutions are anticipated to further stimulate advancements and expansion within the retinal therapeutics market.

Restraints in the Global Retinal Disease Therapeutics Market

The global retinal disease therapeutics market faces several challenges that may hinder its growth. High expenses associated with retinal treatment therapies can limit patient accessibility and adoption. Moreover, patients often report experiencing short-term side effects, along with potential long-term complications like infections and inflammation following procedures such as laser eye surgery. The risk of unintentional scleral perforation during specific surgical techniques, such as pneumatic retinopexy, may further deter patient willingness to undergo treatment. Additionally, inadequate healthcare infrastructure in developing regions poses a significant obstacle to the advancement of the retinal disease therapeutics market.

Market Trends of the Global Retinal Disease Therapeutics Market

The Global Retinal Disease Therapeutics market is poised for significant growth, driven by the emergence of advanced technologies, particularly in retinal gene therapy. Innovations such as Luxturna, which targets the RPE65 gene mutation to treat inherited conditions like Leber's congenital amaurosis, underline a transformative shift in therapeutic approaches. As several promising retinal gene therapies are currently undergoing clinical trials using recombinant viruses, their anticipated approval and market entry are set to further enhance treatment options. Between 2022 and 2028, this advancement in gene therapy is projected to significantly expand the market, catering to the increasing demand for effective solutions for retinal disorders.

Table of Contents

Introduction

Research Methodology

Executive Summary

Market Dynamics & Outlook

Key Market Insights

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2024-2031)

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2024-2031)

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2024-2031)

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2024-2031)

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2024-2031)

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2024-2031)

Global Retinal Disease Therapeutics Market Size & CAGR (2024-2031)

Competitive Intelligence

Key Company Profiles

Conclusion & Recommendations

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기